The Primasun Sleep Apnea Program: What a $300 Million Partnership Proved and Why It Failed

The Sleep Apnea Care Gap Is Not New

Sleep apnea affects an estimated 54 million Americans. Over 80 percent of them have never been diagnosed. The ones who do get diagnosed face a fragmented pathway that can take months or over a year from first suspicion to treatment. Along the way, patients bounce between primary care physicians, sleep specialists, testing facilities, and equipment providers. At every handoff, some percentage of them disappear.

This is not a secret. The sleep medicine community has documented these problems for decades. The question has never been whether the system is broken. The question is whether anyone with the resources to fix it actually will.

In 2018, two of the most powerful organizations in health technology announced they were going to try.

The Ambition Behind Primasun

The partnership brought together an Alphabet precision health subsidiary and the world's largest manufacturer of CPAP devices. The subsidiary contributed expertise in machine learning, predictive analytics, and scalable digital health platforms. The device manufacturer contributed clinical domain knowledge, a global physician network, and what its chief medical officer described as "billions of nights of data" collected from connected CPAP machines.

The stated mission was to study the health and financial impacts of undiagnosed sleep apnea and develop software solutions that enable healthcare providers to more efficiently identify, diagnose, treat, and manage individuals with the condition.

The joint venture would operate as a separate entity from both parent companies. It would hire its own CEO. It would build its own platform. It would run its own clinical studies.

The vision was comprehensive. Identify people at risk. Screen them remotely. Connect them to sleep specialists through telemedicine. Deliver home sleep testing. Interpret results. Initiate therapy. Provide ongoing coaching and support. All virtual. All coordinated through a single digital platform.

This was not an incremental improvement. This was an attempt to replace the entire broken pathway with something better.

Four Years to Launch

The partnership was announced in July 2018. The joint venture did not launch a commercial product until November 2022. That is four years and four months from announcement to market.

During that time, the venture ran a feasibility pilot study in North Carolina and Texas during 2020. It hired a CEO in November 2020. It chose a name, Primasun, in April 2021. It published the pilot study results in January 2022. It finally launched publicly at a healthcare conference in Las Vegas in November 2022.

In January 2023, Primasun joined a global consortium working on standardized sleep measures. That was its last public activity.

By late 2024, the venture had been quietly absorbed back into the device manufacturer. The website went down. The LinkedIn page showed zero employees. The CEO moved on to other ventures. No formal shutdown was ever announced.

The Pilot Study That Proved the Model Works

The clinical data from the Primasun pilot is genuinely impressive. Published in JMIR Formative Research in January 2022, the study tracked 158 participants through a fully virtual sleep apnea diagnostic and treatment pathway.

The researchers recruited participants online. No physician referral was required. Participants completed an online screening questionnaire, then scheduled a video appointment with a board-certified sleep physician. If the physician ordered a home sleep test, the device was shipped directly to the participant's home. After completing the test, participants scheduled a follow-up video appointment to review results.

The journey time results challenged everything we accept as normal in sleep medicine.

From the first physician visit to receiving the home sleep test device: median 7 days. From receiving the device to getting an OSA diagnosis at the follow-up visit: median 12 days. From the first physician visit to a confirmed diagnosis: median 19 days. From diagnosis to starting therapy: median 6 days.

The total journey from initial screening to active therapy was approximately six weeks.

For context, standard-of-care timelines in the United States range from four weeks to over a year just for diagnosis. One Veterans Health Administration analysis found an average of eight to nine months from initial referral to sleep evaluation. A Canadian study documented wait times of 152 days under standard care. In the United Kingdom, the average from referral to therapy initiation is approximately 14 months.

The Primasun pathway compressed this into weeks.

Completion Rates That Should Not Be Possible

The attrition numbers were equally striking. Of participants who scheduled their first appointment, 86 percent completed it. That compares to no-show rates of 21 to 30 percent reported in traditional sleep clinic studies.

Of those who received a home sleep test, 98 percent completed it and returned usable data. Of those who completed the test, 98 percent showed up for their follow-up results appointment.

Of the 114 participants diagnosed with obstructive sleep apnea, 105 were prescribed positive airway pressure therapy. All 105 received their device. Only two withdrew consent during the entire treatment period.

The diagnostic pathway lost less than five percent of participants after the first appointment. In a field where patient attrition is the defining problem, these numbers are remarkable.

Patient Satisfaction Was Real

Participants were not just completing the pathway. They were satisfied with it. The mean satisfaction rating for the diagnostic portion was 4.75 out of 5.0. Eighty-four percent of respondents gave a perfect score. Only two percent rated below a 3.

Registration was rated 4.78 out of 5.0 for ease of use. Onboarding satisfaction was 4.69 out of 5.0.

After 90 days of therapy, overall program satisfaction was 4.3 out of 5.0, with over 81 percent rating the experience as satisfied or very satisfied.

These are not typical numbers for sleep apnea care. They reflect what happens when someone designs a pathway around the patient experience rather than the provider's schedule.

So Why Did It Fail?

This is the question the published study does not answer. The clinical data was strong. The platform worked. The patients were satisfied. The attrition rates were historically low.

And yet by 2024, the entity was gone.

The answer is not in the clinical data. It is in the business model.

The Device-Centric Trap

Look at the treatment pathway in the Primasun study. Every patient diagnosed with OSA was evaluated for positive airway pressure therapy. Of 114 diagnosed, 105 were prescribed PAP. That is 92 percent funneled into a single therapy modality.

PAP therapy means CPAP. And CPAP devices are the core product of the device manufacturer that co-owned the venture.

This is the fundamental conflict. A joint venture co-owned by the world's largest CPAP manufacturer will never offer therapy options that compete with CPAP. It does not matter how patient-centric the press releases sound. The business model requires patients to land on the device the parent company sells.

The published research on CPAP adherence tells us what happens next. Roughly half of patients prescribed CPAP therapy cannot or will not use it consistently over the long term. They struggle with mask discomfort, claustrophobia, pressure intolerance, lifestyle incompatibility, or simply the burden of sleeping attached to a machine every night. Some abandon therapy within the first week. Others gradually reduce use over months until the machine sits in a closet.

A program with only one therapy endpoint loses half its patients after diagnosis. Not because the diagnosis was wrong. Not because the platform failed. Because the therapy option did not work for them, and there was no Plan B.

The Primasun study itself hints at this limitation. Nine of the 114 diagnosed patients were diagnosed with OSA but not prescribed PAP therapy. The study does not elaborate on what those nine patients were offered instead. It does note that participants who were "recommended non-PAP treatment options" were "exited from the study and connected to additional local clinical resources when needed."

Exited from the study. That is what happens when the program has no pathway for patients who need something other than CPAP. They leave.

This Problem Is Not Unique to One Venture

Every sleep care initiative funded by a device manufacturer faces the same structural limitation. The manufacturer's revenue depends on device sales. The program exists to generate more device sales. Clinical language about "patient-centered care" does not change the financial incentives.

When a device company runs a screening program, it is looking for customers, not patients. The distinction matters. A customer needs to buy the product. A patient needs effective therapy, whatever form that takes.

There are patients for whom CPAP is the right answer. It is effective, well-studied, and insurance-covered. For moderate to severe obstructive sleep apnea, it remains the most established treatment option.

But there are also patients for whom CPAP is not the right answer. Patients with mild to moderate OSA who may respond well to alternative therapies. Patients who have already tried CPAP and abandoned it. Patients whose lifestyle, sleep position, or personal tolerance makes CPAP impractical. Patients who need an effective option for travel, camping, or situations where power is unavailable.

A truly patient-centered program serves all of them. A device-centered program serves only the ones who will use the device.

What the Primasun Data Actually Proved

Strip away the business model failure and the clinical data tells a clear story.

Virtual care works for sleep apnea. Patients will complete an online screening, attend telemedicine appointments, use a home sleep test, and follow through on treatment when the pathway is designed around their convenience.

Friction kills patient engagement. When you remove the scheduling barriers, the geographic barriers, the transportation barriers, and the multi-provider coordination barriers, patients show up. Ninety-eight percent completion on home sleep testing. Ninety-eight percent return for results. These numbers prove that patients want help. They just need a pathway that does not punish them for seeking it.

Speed matters. A 19-day median from first visit to diagnosis is not just faster than standard care. It changes the psychology of the patient experience. Momentum is preserved. The patient stays engaged. There is no six-month gap where motivation evaporates.

Coaching and support improve retention. The program provided health coaches via messaging throughout the 90-day therapy period. This is not a technology insight. It is a clinical one. Patients on therapy need ongoing human support, not just a device and a manual.

What Comes Next

The Primasun experiment left behind two things. A peer-reviewed dataset proving virtual sleep care works. And a cautionary tale about what happens when clinical innovation is subordinated to a device company's business model.

The dataset is still valuable. The researchers who produced it were rigorous. The study was registered on ClinicalTrials.gov, conducted under IRB oversight, and published in a peer-reviewed journal. The journey metrics, completion rates, and satisfaction scores represent a genuine benchmark for what virtual sleep care can achieve.

The cautionary tale is equally valuable. It demonstrates that the sleep apnea care gap will not be closed by any program designed primarily to sell devices. The gap exists precisely because the current system prioritizes devices over patients, reimbursement over outcomes, and provider convenience over patient access.

Closing the gap requires something structurally different. A care pathway that is agnostic to the therapy endpoint. One that offers multiple treatment options based on clinical indication, not commercial interest. One that keeps patients in the care continuum when the first option does not work, rather than exiting them from the program. One that monitors long-term outcomes, not just initial device setup.

The Primasun pilot study proved that the technology and the clinical workflow exist to diagnose and treat sleep apnea in weeks rather than months. That finding stands regardless of what happened to the company.

The next challenge is building a program that uses those capabilities in service of the patient, not the device manufacturer. That program does not need to be invented. It needs to be assembled by people who understand both the clinical pathway and the structural incentives that have sabotaged every previous attempt.

The data says it can be done. The market says it needs to be done. The question is whether anyone will build it for the right reasons.